Captopri ๐
Related Subjects:
|Hypertension
|Acute Heart Failure
|Chronic Heart Failure
โ ๏ธ First-dose hypotension is common.
๐ก Start at the lowest dose, ideally at night with the patient in bed.
More frequent when used for heart failure than for hypertension.
If it occurs โ lie patient flat, raise legs, and give IV fluids if BP remains low.
- ๐น Competitively inhibits angiotensin-converting enzyme (ACE).
- ๐ Prevents formation of angiotensin II, a potent vasoconstrictor.
- โฌ๏ธ Increases bradykinin โ cough and angioedema.
- ๐ Reduces BP without reflex tachycardia.
- ๐ Always check U&Es, document starting BP, and identify a target BP before initiation.
๐ฏ Indications / Dose
- ๐ Heart failure: Start 6.25 mg PO TDS โ titrate to max 50 mg TDS.
- โค๏ธ Hypertension: Start 12.5 mg PO TDS โ titrate to max 50 mg TDS.
- ๐งช Diabetes with nephropathy: Start 6.25 mg PO TDS โ titrate to max 50 mg TDS.
โ ๏ธ Cautions
- Less effective as monotherapy in African-Caribbean patients (consider CCBs or thiazides first per NICE guidance).
โ Contraindications
- ๐ซ Pregnancy and breastfeeding โ teratogenic.
- โ ๏ธ Severe aortic stenosis or hypertrophic cardiomyopathy.
- ๐ซ Bilateral renal artery stenosis.
- โ ๏ธ Pre-existing hyperkalaemia.
๐ Interactions
- โ ๏ธ With alteplase (tPA) โ angioneurotic oedema risk in acute stroke thrombolysis.
- โ Avoid NSAIDs (reduce efficacy, worsen renal function).
- โฌ๏ธ Hyperkalaemia risk when combined with potassium-sparing diuretics, ARBs, or supplements.
โ ๏ธ Side Effects
- ๐ Postural hypotension (especially first dose, see above).
- ๐คข Nausea, vomiting.
- ๐จ Cough (bradykinin-related).
- ๐ฎ Angioedema (rare but serious).
- ๐
Altered taste (metallic taste).
- ๐ง Worsening renal function in bilateral renal artery stenosis.
- ๐งช Hyperkalaemia.
๐ Monitoring
- ๐ Check renal function & electrolytes at 4 days and 2 weeks after initiation.
- ๐ Repeat 1 week after any dose increase.
- โ ๏ธ Stop or reduce if creatinine โ >30% or Kโบ >6.0 mmol/L.